medigraphic.com
SPANISH

Revista de Endocrinología y Nutrición

ISSN 0188-9796 (Print)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2010, Number 2

<< Back Next >>

Rev Endocrinol Nutr 2010; 18 (2)

Combined therapy with rosiglitazone and metformin in the prevention of type 2 diabetes mellitus (The CANOE trial)

Espinoza PD
Full text How to cite this article

Language: Spanish
References: 6
Page: 120-121
PDF size: 148.02 Kb.


Key words:

No keywords

Text Extraction

No abstract


REFERENCES

  1. The DECODE Study Group. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care 1999; 22: 1667-71.

  2. Knowler WC, Barret-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 2002; 346: 393-403.

  3. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.

  4. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803.

  5. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096-1105.

  6. Petersen KF, Krssak M, Inzucchi S et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827-31.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Endocrinol Nutr. 2010;18